ACTEMRA
Transform living
Press Releases
RoACTEMRA approved in Europe to treat patients suffering from Rheumatoid Arthritis
Basel, 21 January 2009
First in class therapy offers new treatment option to patients with moderate to severe form of the disease
Roche and FDA Agree on Pathway Towards U.S. Approval of Actemra (tocilizumab)
Basel, 4 December 2008
Swissmedic today approved Actemra for use in Rheumatoid Arthritis
RoACTEMRA Receives Positive Opinion in Europe for the Treatment of Rheumatoid Arthritis
Basel, 21 November 2008
First-in-class therapy represents a novel approach to treat patients with moderate to severe rheumatoid arthritis
New data shows ACTEMRA inhibits progression of joint destruction and improves physical function of patients with Rheumatoid Arthritis
Basel, 27 October 2008
Fifth phase III study also confirms significant rate of disease remission in patients treated with ACTEMRA
FDA Issues Complete Response Letter to Roche for Actemra Biologics License Application
Basel, 18. September 2008
No New Clinical Studies Requested
FDA Advisory Committee recommends approval of Actemra for the treatment of rheumatoid arthritis
Basel, 30 July 2008
First interleukin-6 inhibitor (IL-6) to offer new therapeutic option for rheumatoid arthritis
New data reveals Actemra is the first and only biologic drug to show superiority over current standard of care in rheumatoid arthritis
Embargo, 13 June 2008
Two new international studies also show high remission rates in patients treated with Actemra
Actemra inhibits joint damage and improves physical function of patients with Rheumatoid Arthritis
Basel, 9 May 2008
Fifth phase III study for Actemra adds to body of evidence that Actemra is an important breakthrough in the treatment of rheumatoid arthritis
Actemra approved in Japan to treat patients with rheumatoid arthritis
Basel, 16 April 2008
First approval for Actemra in rheumatoid arthritis worldwide
Novel drug ACTEMRA significantly improves the debilitating symptoms of Rheumatoid Arthritis in patients who have an inadequate response to standard therapy
Basel, 22 March 2008
Pivotal Phase III OPTION study published today in The Lancet